Proposal for magnetic resonance imaging-guided salvage radiotherapy for prostate cancer.

BACKGROUND: A subset of patients experience a biochemical recurrence following radical prostatectomy. Radiotherapy can salvage those patients, provided that all disease is encompassed within the target volume. We hypothesized that this can be achieved more adequately with magnetic resonance imaging (MRI)-guided treatment planning. MATERIAL AND METHODS: From January 2009 to April 2014, 183 patients were referred to our department for salvage radiotherapy (SRT). According to protocol, patients received a planning computed tomography (CT) as well as an MRI in treatment position. All MRI scans were retrospectively reviewed by an experienced uro-radiologist. RESULTS: Median prostate-specific antigen (PSA) value at time of referral was 0.3 ng/ml (range 0.02-4.7 ng/ml). MRI did not show any suspected macroscopic disease in 137 patients (75%). In 46 (25%) patients, MRI did indicate a pelvic recurrence. The mean PSA level was significantly higher in patients with a suspected recurrence on MRI (0.4 vs. 1.4 ng/ml, p < .001) on a Student's t-test. The mean follow-up was 33 months (range 5-69 months). Biochemical disease-free survival (bDFS) was significantly worse in patients with suspected disease on MRI [hazard ratio (HR) 2.9, p < .0001]. bDFS was significantly worse in the subgroup where the macroscopic recurrences on MRI received a lower radiation dose (HR 3.4, p = .01). CONCLUSION: MRI detects loco-regional disease in a substantial subset of patients with a biochemical recurrence after prostatectomy, especially in a PSA above 0.5 µg/l. Lack of MRI-based dose escalation on these macroscopic recurrences could explain some of the biochemical progression observed after SRT.

Apparent diffusion coefficient measurements as very early predictive markers of response to chemotherapy in hepatic metastasis: a preliminary investigation of reproducibility and diagnostic value.

PURPOSE: To evaluate the reproducibility and diagnostic value of apparent diffusion coefficient (ADC) as an early predictor of response to chemotherapy of liver metastasis in routine clinical practice. MATERIALS AND METHODS: A prospective study of 20 patients with histologically proven primary tumors with liver metastases was undertaken. Diffusion weighted MRI was performed twice before and 12-14 days after the start of treatment. Absolute and liver normalized ADC values were calculated. Bland Altman statistics were used to assess the reproducibility of ADC change for predicting lesion response as measured by RECIST. RESULTS: Nineteen of 31 metastases responded. Significant increases in absolute and normalized ADC values were found in responding (mean +208.7 × 10(-6) m(2)/s and +18% respectively, both P < 0.001) compared with nonresponding lesions (mean +98.6 × 10(-6) m(2)/s and 2%, respectively, P = 0.09 and 0.519). Reproducibility was better using normalized ADC compared with absolute ADC values (within patient coefficient of variability 8.0% and 10.1%, respectively). Using the repeatability threshold of ±22.3% for normalized ADC, only 8 of 19 responding and all but one nonresponding lesions could be prospectively detected. CONCLUSION: Increases in ADC values in responding liver metastases occurred within days after the start of chemotherapy but were of smaller magnitude than the variability of ADC measurement. These preliminary data suggest that the presently used technique is not reliable enough to predict final response at such an early time point in individual lesions.

Pancreatic hemi-agenesis in MEN1: A clinical report.

We first describe a patient with multiple endocrine neoplasia type 1 (MEN1) and dorsal pancreatic hemi-agenesis. Previously, pancreas divisum has been reported in MEN1. Recent data in mice have elucidated the molecular mechanisms of pancreatic endoderm specification. Disinhibition of hedgehog signaling appears to be important in how Gata4 and Gata6 variants cause pancreatic agenesis. Disinhibition of hedgehog signaling has also been observed in Men1 knockout pancreatic islets. Although we cannot exclude a spurious association between dorsal pancreatic hemi-agenesis and MEN1 in our patient, we argue that developmental abnormalities of the pancreas may have to be considered as possibly related to the MEN1 phenotype.

Diagnosis of liver metastases: can diffusion-weighted imaging (DWI) be used as a stand alone sequence?

OBJECTIVES: To evaluate if diffusion-weighted MRI (DWI) can replace gadolinium-enhanced MRI (Gd-MRI) for diagnosing liver metastases. The diagnostic accuracy of both techniques alone and in combination are compared. MATERIALS AND METHODS: Sixty-eight patients with histologically proven primary extrahepatic tumors were included in this retrospective study. Lesions included 62 metastases and 130 benign lesions. Three image sets (unenhanced T1 and T2/gadolinium enhanced T1 (Gd-MRI), DWI and combination of both) were reviewed independently by 3 observers. The areas under the receiver operating characteristic curves (A(z)), sensitivity and specificity for the 3 image sets were compared. The standard of reference was either histopathology or multi-modality and clinical follow-up. RESULTS: Pooled data showed higher diagnostic accuracy for the combined set (A(z)=0.93) compared to Gd-MRI (p=0.001) and DWI (p<0.0001). No difference was found between the performance of Gd-MRI and DWI (p=0.09). Sensitivity for the combined set was higher than Gd-MRI (p=0.0003) and DWI (p=0.0034). Specificity for DWI was lower than Gd-MRI (p<0.0001) and the combined set (p<0.0001). CONCLUSION: The diagnostic performance of DWI is equal to that of Gd-MRI. DWI alone can be used in patients where gadolinium contrast administration is not allowed. Combination of Gd-MRI and DWI significantly increases diagnostic accuracy.